Skip to content
10-Q

Quarterly Report

Rocket Pharmaceuticals, Inc. RCKT RCKTW

0001193125-26-211873

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 109.19M sh
Shares Diluted Q1 2026 · Mar 31, 2026 112.13M sh
Shares Diluted Q1 2026 · Mar 31, 2025 110.09M sh
Capex Q1 2026 · Mar 31, 2026 $93K
Capex Q1 2026 · Mar 31, 2025 $364K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$45.39M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$55.79M
Short Term Investments Q1 2026 · Mar 31, 2026 $94.77M
Short Term Investments Q1 2026 · Dec 31, 2025 $111.37M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $49.61M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $77.56M
Stockholders Equity Q1 2026 · Mar 31, 2026 $238.04M
Stockholders Equity Q1 2026 · Dec 31, 2025 $277.22M
Stockholders Equity Q1 2026 · Mar 31, 2025 $412.14M
Stockholders Equity Q1 2026 · Dec 31, 2024 $463.23M
Current Liabilities Q1 2026 · Mar 31, 2026 $24.47M
Current Liabilities Q1 2026 · Dec 31, 2025 $30.21M
Total Liabilities Q1 2026 · Mar 31, 2026 $47.37M
Total Liabilities Q1 2026 · Dec 31, 2025 $53.23M
Current Assets Q1 2026 · Mar 31, 2026 $149.83M
Current Assets Q1 2026 · Dec 31, 2025 $192.73M
Total Assets Q1 2026 · Mar 31, 2026 $285.41M
Total Assets Q1 2026 · Dec 31, 2025 $330.45M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.42
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.56
Eps Basic Q1 2026 · Mar 31, 2026 −$0.42
Eps Basic Q1 2026 · Mar 31, 2025 −$0.56
Sga Expense Q1 2026 · Mar 31, 2026 $17.06M
Sga Expense Q1 2026 · Mar 31, 2025 $28.45M
Rd Expense Q1 2026 · Mar 31, 2026 $31.45M
Rd Expense Q1 2026 · Mar 31, 2025 $35.94M
Net Income Q1 2026 · Mar 31, 2026 −$47.59M
Net Income Q1 2026 · Mar 31, 2025 −$61.33M
Operating Income Q1 2026 · Mar 31, 2026 −$48.51M
Operating Income Q1 2026 · Mar 31, 2025 −$64.39M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $0